NASDAQ:SLRN Acelyrin (SLRN) Stock Price, News & Analysis $7.00 +0.27 (+4.01%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.70▼$7.1050-Day Range$3.86▼$7.0652-Week Range$3.67▼$29.88Volume1.91 million shsAverage Volume1.10 million shsMarket Capitalization$693.21 millionP/E RatioN/ADividend YieldN/APrice Target$12.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Acelyrin alerts: Email Address Acelyrin MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside82.9% Upside$12.80 Price TargetShort InterestBearish10.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 3 Articles This WeekInsider TradingSelling Shares$7 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.33) to ($4.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector577th out of 936 stocksPharmaceutical Preparations Industry262nd out of 436 stocks 3.3 Analyst's Opinion Consensus RatingAcelyrin has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAcelyrin has only been the subject of 2 research reports in the past 90 days.Read more about Acelyrin's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.84% of the float of Acelyrin has been sold short.Short Interest Ratio / Days to CoverAcelyrin has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Acelyrin has recently decreased by 3.95%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAcelyrin does not currently pay a dividend.Dividend GrowthAcelyrin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRN. Previous Next 2.6 News and Social Media Coverage News SentimentAcelyrin has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Acelyrin this week, compared to 3 articles on an average week.Search Interest10 people have searched for SLRN on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows5 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acelyrin insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7.00 in company stock.Percentage Held by Insiders13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acelyrin's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acelyrin are expected to decrease in the coming year, from ($3.33) to ($4.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acelyrin is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acelyrin is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcelyrin has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Acelyrin's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Acelyrin Stock (NASDAQ:SLRN)Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Read More SLRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRN Stock News HeadlinesJuly 20, 2024 | americanbankingnews.comContrasting Acelyrin (NASDAQ:SLRN) & UroGen Pharma (NASDAQ:URGN)May 29, 2024 | globenewswire.comACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024July 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.May 18, 2024 | finance.yahoo.comAcelyrin, Inc. (SLRN)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising PipelineMay 15, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024May 15, 2024 | markets.businessinsider.comACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic AdvancementsMay 9, 2024 | marketwatch.comAcelyrin Founder Steps Down as CEOJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.May 9, 2024 | msn.comAcelyrin names Mina Kim as new Chief Executive OfficerMay 9, 2024 | finance.yahoo.comACELYRIN, INC. Announces Leadership TransitionMay 9, 2024 | globenewswire.comACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesApril 29, 2024 | globenewswire.comACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024April 1, 2024 | msn.comStocks Pressured as Bond Yields Jump on Strength in US ManufacturingApril 1, 2024 | markets.businessinsider.comACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingMarch 28, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023March 28, 2024 | finance.yahoo.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 28, 2024 | globenewswire.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsSee More Headlines Receive SLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLRN CUSIPN/A CIK1962918 Webwww.acelyrin.com Phone805-730-0360FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$12.80 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+82.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-381,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.33% Return on Assets-32.55% Debt Debt-to-Equity RatioN/A Current Ratio13.27 Quick Ratio13.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.74 per share Price / Book1.04Miscellaneous Outstanding Shares99,030,000Free Float85,559,000Market Cap$693.21 million OptionableOptionable Beta2.56 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMs. Melanie Gloria B.S.N. (Age 46)Chief Operating Officer Comp: $667.52kMs. Mina Kim (Age 50)CEO & Director Mr. Gilbert M. Labrucherie J.D. (Age 52)CFO & Chief Business Officer Mr. Tyler MarciniakHead of Investor Relations & CommunicationsMs. Sanam Pangali J.D.Chief Legal Officer & Head of PeopleDr. Paul M. Peloso M.D. (Age 66)M.Sc., Chief Medical Officer Ms. Suzy Buckhalter CPASenior Director of Finance & AccountingMr. Kenneth A. Lock (Age 50)Chief Commercial Officer Dr. Shephard Mpofu M.D.Chief Medical OfficerMs. Patricia A. Turney (Age 57)Chief Technical Operations Officer More ExecutivesKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXAmneal PharmaceuticalsNASDAQ:AMRXDeciphera PharmaceuticalsNASDAQ:DCPHBausch Health CompaniesNYSE:BHCSyndax PharmaceuticalsNASDAQ:SNDXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 41,058 shares on 7/26/2024Ownership: 0.226%Nisa Investment Advisors LLCBought 14,057 shares on 7/20/2024Ownership: 0.014%Daniel J BeckerSold 1 sharesTotal: $6.86 ($6.86/share)SG Americas Securities LLCBought 11,654 shares on 7/12/2024Ownership: 0.012%Opaleye Management Inc.Sold 2,566,138 shares on 5/29/2024Ownership: 1.596%View All Insider TransactionsView All Institutional Transactions SLRN Stock Analysis - Frequently Asked Questions How have SLRN shares performed this year? Acelyrin's stock was trading at $7.46 at the start of the year. Since then, SLRN shares have decreased by 6.2% and is now trading at $7.00. View the best growth stocks for 2024 here. How were Acelyrin's earnings last quarter? Acelyrin, Inc. (NASDAQ:SLRN) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.57. When did Acelyrin IPO? Acelyrin (SLRN) raised $540 million in an initial public offering (IPO) on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share. Who are Acelyrin's major shareholders? Acelyrin's top institutional shareholders include Bank of New York Mellon Corp (0.23%), Nisa Investment Advisors LLC (0.01%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston. View institutional ownership trends. How do I buy shares of Acelyrin? Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.